MALVERN, Pa., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical
company, today announced that it intends to offer and sell, subject to market conditions, up to $75,000,000 of shares of its common
stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by
Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of
its common stock sold in the public offering on the same terms and conditions. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Company,
L.L.C., Guggenheim Securities, LLC, and JMP Securities LLC are acting as co-managers for the offering.
A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed
with the Securities and Exchange Commission (SEC) on November 2, 2016 and declared effective by the SEC on November 14, 2016.
The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the
SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying
prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 821-7388; or Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6132, email:
syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered,
nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other
jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic
dermatology. Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment
gaps exist. Aclaris is based in Malvern, Pennsylvania.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Aclaris Therapeutics, Inc., including
statements about Aclaris’s anticipated public offering, anticipated use of proceeds and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties related to market conditions and the completion
of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and
such other factors as are set forth in the risk factors detailed in Aclaris’s Annual Report on Form 10-K for the year ended
December 31, 2016, Aclaris’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and Aclaris’s other filings with the
SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent
Aclaris’s views as of the date hereof. Aclaris anticipates that subsequent events and developments will cause Aclaris’s views to
change. However, while Aclaris may elect to update these forward-looking statements at some point in the future, Aclaris
specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing
Aclaris’s views as of any date subsequent to the date hereof.
Contact: Aclaris Contact Michael Tung, M.D. Vice President / Investor Relations 484-329-2140 mtung@aclaristx.com Media Contact Mariann Caprino TogoRun 917-242-1087 M.Caprino@togorun.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/f070dd10-8174-4c0b-b7f6-dd7ec69540ae?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNjkyNDg1OA==)